MedTrace Logo

ADJUnct Semaglutide Treatment in Type 1 Diabetes

NCT05537233 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2025-09-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.

Conditions

Interventions

DRUG

Semaglutide

Semaglutide up to 1 mg per week in addition to standard closed-loop therapy

DRUG

Placebo

Injection placebo up to 1 mg per week in addition to standard closed-loop therapy

Sponsors & Collaborators

  • Juvenile Diabetes Research Foundation

    collaborator OTHER

  • Viral N. Shah

    lead OTHER

Principal Investigators

  • Viral N Shah, MD · Indiana University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-11
Primary Completion
2024-08-06
Completion
2024-08-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05537233 on ClinicalTrials.gov